Helicobacter pylori Infection and Gastric Cancer Risk: Evaluation of 15 H. pylori Proteins Determined by Novel Multiplex Serology

Abstract

Infection with Helicobacter pylori is a major cause of gastric cancer (GC). The association likely has been underestimated in the past due to disease-related clearance of the infection. On the other hand, only a minority of the infected individuals develop GC, and better risk stratification is therefore highly desirable. We aimed to assess the association of GC with antibodies to 15 individual H. pylori proteins, determined by novel multiplex serology, to identify potentially relevant risk markers. This analysis was based on 123 GC cases aged 50 to 74 years and 492 age-matched and sex-matched controls from Saarland, Germany. Eight of the antibodies were significantly associated with noncardia GC and seven of them were significantly related to GC at any site. More pronounced associations were observed for noncardia GC; adjusted odds ratios (95% confidence intervals) ranged from 1.60 (1.01-2.54) for HyuA to 5.63 (3.20-9.91) for cytotoxin-associated antigen A (CagA). A dose-response relationship was found between the number of seropositivities and GC (P < 0.001). The seropositivities of CagA and GroEL were found to be independent predictors of GC, which were strongly related to GC risk in a dose-response manner (P < 0.001). In conclusion, GroEL was identified as a new independent risk marker that may contribute to enhanced quantification of H. pylori-related GC risk. [Cancer Res 2009;69(15):6164-70]

A Novel Line Immunoassay Based on Recombinant Virulence Factors Enables Highly Specific and Sensitive Serologic Diagnosis of Helicobacter pylori Infection

“…Also, it has been shown in different studies that these two antigens are found more often in patients with gastrointestinal disorders (23). These findings make GroEL and HcpC interesting for serological testing, as they show good immune responses in infected patients.…”

Vitamin D Receptor Genotype rs731236 (Taq1) and Breast Cancer Prognosis

“…The state of Saarland was chosen, inter alia, as highly efficient, and reliable long-term follow-up of patients with cancer is possible through the Saarland Cancer Registry (12). In the ESTHER II study more than 2,000 patients of ages 50 to 74 years and diagnosed with various forms of cancer were recruited between January 2001 and December 2003 (13); in the VERDI study 908 patients of ages 80 years or less with a first diagnosis of breast, colorectal, or gastric cancer were recruited between October 1996 and February 1998 (14).…”

“…Details of both studies have been reported elsewhere (13)(14)(15). In the VERDI study exact ascertainment of participation rates of patients with breast cancer approached by their physician was possible, and participation was found to be very high (387 of 401 eligible women, 96.5%).…”

Unraveling the interactions between environmental factors and genetic polymorphisms in non-Hodgkin lymphoma risk

“…For example, determining immunological fingerprints to clarify the role of past infections in lymphomagenesis may employ technologies such as multiplex serology (e.g., Luminex ® technology) in large-scale epidemiological studies. Recently, data on 15 H. pylori proteins in the context of chronic atrophic gastritis and gastric cancer risk were published [64,65], and similar approaches may improve internal exposure assessment for NHL and facilitate gene-environment ana lysis in H. pylori-associated MALT lymphoma. Detailed phenotyping of NHL subtypes that incorporate genetic, epigenetic and other molecular data may also improve the detection of potential interactions.…”